12 July 2023
12 July 2023
More restrictive LGBTQ+ bills are being passed in the US that might negatively impact transgender individuals in clinical trials.
To that end, the company presented positive top-line Phase III results for its once-daily stimulant for ADHD.
The biologics company has released data on its trial for atopic dermatitis treatment.
The trial will include approximately 100 patients hospitalised for aneurysmal subarachnoid haemorrhage.
Patients will receive a once daily oral dose of CT1812 for 24 months to determine if it can slow disease progression.
Biological activity will be measured by viral replication in the tumour while clinical response will be evaluated by iRECIST.
Out of 40 patients, seven patients had Grade 5 fatal TEAEs while five reported Grade 3 or Grade 4 respiratory-related TEAEs.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
